Function and regulation of Dyrk1A: towards understanding Down syndrome

[1]  G. Neri,et al.  Faculty Opinions recommendation of Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. , 2009 .

[2]  M. Nieto,et al.  Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A , 2009, Journal of Cell Science.

[3]  W. Mobley,et al.  The “Down Syndrome Critical Region” Is Sufficient in the Mouse Model to Confer Behavioral, Neurophysiological, and Synaptic Phenotypes Characteristic of Down Syndrome , 2009, The Journal of Neuroscience.

[4]  H. Katus,et al.  DYRK1A Is a Novel Negative Regulator of Cardiomyocyte Hypertrophy* , 2009, The Journal of Biological Chemistry.

[5]  Min-Su Jung,et al.  QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[6]  Desmond J. Smith,et al.  Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A , 2009, PloS one.

[7]  J. Delabar,et al.  The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. , 2008, Developmental cell.

[8]  B. Lutz,et al.  The down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4 , 2008, Neuroscience.

[9]  X. Estivill,et al.  Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. , 2008, American journal of human genetics.

[10]  J. Wegiel,et al.  The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome , 2008, Acta Neuropathologica.

[11]  Alberto C. S. Costa,et al.  Acute Injections of the NMDA Receptor Antagonist Memantine Rescue Performance Deficits of the Ts65Dn Mouse Model of Down Syndrome on a Fear Conditioning Test , 2008, Neuropsychopharmacology.

[12]  Reinhard Ullmann,et al.  Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. , 2008, American journal of human genetics.

[13]  M. Dierssen,et al.  Down syndrome and the genes of human chromosome 21: current knowledge and future potentials , 2008, Cytogenetic and Genome Research.

[14]  J. Galceran,et al.  Bmc Molecular Biology Characterization of the Human Dyrk1a Promoter and Its Regulation by the Transcription Factor E2f1 , 2022 .

[15]  F. Tejedor,et al.  The spatio‐temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development , 2008, The European journal of neuroscience.

[16]  Hyun-Jeong Cho,et al.  Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease , 2008, Journal of neurochemistry.

[17]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[18]  Hyun-Jeong Cho,et al.  DYRK1A-mediated Hyperphosphorylation of Tau , 2007, Journal of Biological Chemistry.

[19]  C. Epstein,et al.  Synaptic and cognitive abnormalities in mouse models of down syndrome: Exploring genotype‐phenotype relationships , 2007, The Journal of comparative neurology.

[20]  K. Chung,et al.  Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome , 2007, Molecular and Cellular Neuroscience.

[21]  M. Pletnikov,et al.  Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. , 2007, Human molecular genetics.

[22]  Fabian Fernandez,et al.  Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome , 2007, Nature Neuroscience.

[23]  J. Wegiel,et al.  Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome , 2007, Neuroscience Letters.

[24]  T. Iwatsubo,et al.  Dyrk1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation* , 2006, Journal of Biological Chemistry.

[25]  K. Kim,et al.  A repressor complex, AP4 transcription factor and geminin, negatively regulates expression of target genes in nonneuronal cells , 2006, Proceedings of the National Academy of Sciences.

[26]  Jung Tae Lee,et al.  Putative therapeutic agents for the learning and memory deficits of people with Down syndrome. , 2006, Bioorganic & medicinal chemistry letters.

[27]  Xin Gao,et al.  NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 , 2006, Nature.

[28]  Y. Gwack,et al.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT , 2006, Nature.

[29]  Hey-kyeong Jeong,et al.  DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects , 2006, Neurobiology of Disease.

[30]  I. Ferrer,et al.  Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models , 2005, Neurobiology of Disease.

[31]  G. Elston,et al.  Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/− mouse , 2005, Neurobiology of Disease.

[32]  K. Chung,et al.  Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase‐3 in hippocampal neuroprogenitor cells , 2005, Journal of neuroscience research.

[33]  C. Epstein,et al.  Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome , 2005, Neuropharmacology.

[34]  P. Lochhead,et al.  Activation-Loop Autophosphorylation Is Mediated by a Novel Transitional Intermediate Form of DYRKs , 2005, Cell.

[35]  C. Epstein,et al.  Synaptic structural abnormalities in the Ts65Dn mouse model of down syndrome , 2004, The Journal of comparative neurology.

[36]  Su Young Choi,et al.  Regulation of Dyrk1A kinase activity by 14-3-3. , 2004, Biochemical and biophysical research communications.

[37]  A. V. Skurat,et al.  Phosphorylation of Ser640 in Muscle Glycogen Synthase by DYRK Family Protein Kinases* , 2004, Journal of Biological Chemistry.

[38]  X. Estivill,et al.  DYRK1A accumulates in splicing speckles through a novel targeting signal and induces speckle disassembly , 2003, Journal of Cell Science.

[39]  M. Trabucchi,et al.  Aggressive behaviour associated with donepezil treatment: a case report , 2003, International journal of geriatric psychiatry.

[40]  X. Estivill,et al.  Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice , 2002, Molecular and Cellular Biology.

[41]  I. Lott,et al.  Down syndrome and Alzheimer disease: response to donepezil. , 2002, Archives of neurology.

[42]  X. Estivill,et al.  Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. , 2001, Human molecular genetics.

[43]  N. Lobaugh,et al.  Piracetam therapy does not enhance cognitive functioning in children with down syndrome. , 2001, Archives of pediatrics & adolescent medicine.

[44]  X. Estivill,et al.  Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. , 1999, Genomics.

[45]  C. Epstein,et al.  Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Rapoport,et al.  Altered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome , 1997, Neuropharmacology.

[47]  Jan-Fang Cheng,et al.  Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome , 1997, Nature Genetics.

[48]  T. Glover,et al.  Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome "critical region". , 1996, Genomics.

[49]  X. Estivill,et al.  A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. , 1996, Human molecular genetics.

[50]  M. Pulsifer,et al.  The neuropsychology of mental retardation , 1996, Journal of the International Neuropsychological Society.

[51]  A. Schürmann,et al.  Dyrk, a Dual Specificity Protein Kinase with Unique Structural Features Whose Activity Is Dependent on Tyrosine Residues between Subdomains VII and VIII (*) , 1996, The Journal of Biological Chemistry.

[52]  R. Bronson,et al.  A mouse model for Down syndrome exhibits learning and behaviour deficits , 1995, Nature Genetics.

[53]  M Heisenberg,et al.  minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila , 1995, Neuron.

[54]  C. Disteche,et al.  Down syndrome phenotypes: the consequences of chromosomal imbalance. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[55]  N. Cairns,et al.  Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. , 1991, The Biochemical journal.

[56]  S. Pulst,et al.  Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. , 1990, American journal of human genetics.

[57]  A. Aurias,et al.  Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. J. Driscoll,et al.  Molecular genetic approach to the characterization of the "Down syndrome region" of chromosome 21. , 1989, Genomics.

[59]  D. Mann,et al.  The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome , 1989, Journal of the Neurological Sciences.

[60]  D. Patterson.  The causes of Down syndrome. , 1987, Scientific American.

[61]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[62]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[63]  P. Burger,et al.  The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. , 1973, The American journal of pathology.

[64]  C. Shaw,et al.  Presenile dementia and Alzheimer's disease in mongolism. , 1969, Brain : a journal of neurology.

[65]  J. Lejeune,et al.  [Study of somatic chromosomes from 9 mongoloid children]. , 1959, Comptes rendus hebdomadaires des seances de l'Academie des sciences.

[66]  T. Uema,et al.  The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. , 2007, Human molecular genetics.

[67]  T. Iwatsubo,et al.  Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. , 2006, The Journal of biological chemistry.

[68]  J. Galceran,et al.  The MNB/DYRK1A protein kinase: genetic and biochemical properties. , 2003, Journal of neural transmission. Supplementum.

[69]  J. Galceran,et al.  The MNB/DYRK1A protein kinase: neurobiological functions and Down syndrome implications. , 2003, Journal of neural transmission. Supplementum.

[70]  H. Joost,et al.  Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. , 1999, Progress in nucleic acid research and molecular biology.

[71]  B. L. Shapiro.  The Down syndrome critical region. , 1999, Journal of neural transmission. Supplementum.

[72]  M. K. McCormick.  Molecular genetic approach to the characterization of the ‘Down syndrome region’ of chromosome 21 , 1989 .